Crossmark

Efficacy and safety of orforglipron 12 mg versus orforglipron 36 mg maintenance dose among patients with obesity with or without diabetes: a systematic review and comprehensive meta-analysis

Crossref DOI link: https://doi.org/10.1186/s12902-026-02538-x

Published Online: 2026-09-15

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hegaz, Mohamed Gamal https://orcid.org/0009-0000-8825-7772
Aboud, Mohammad Yassin Al https://orcid.org/0009-0003-5341-4258
Kamel, Abanoub I. I. https://orcid.org/0009-0008-4512-8565
Naveed, Muhammad Abdullah

Elsayed, Omar Gamal

Sorathia, Aqsa Zoey https://orcid.org/0009-0002-6411-8086
License Information

Text and Data Mining valid from 2026-09-15

Version of Record valid from 2026-09-16
More Information

Article History

Received: 18 June 2026

Accepted: 1 September 2026

First Online: 15 September 2026

Declarations

Ethical approval: No humans participate in this study, and informed consent is not required.

Consent to participate: Not applicable.

Consent for publication: Not applicable.

Competing interests: The authors declare no competing interests.

Document is current

Any future updates will be listed below